Jennison Associates LLC Sells 357,965 Shares of Xylem Inc. $XYL

Jennison Associates LLC lowered its holdings in shares of Xylem Inc. (NYSE:XYL) by 56.5% in the first quarter, Holdings Channel.com reports. The institutional investor owned 275,683 shares of the industrial products company’s stock after selling 357,965 shares during the period. Jennison Associates LLC’s holdings in Xylem were worth $32,944,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. J. Stern & Co. LLP grew its position in Xylem by 12,326.6% in the fourth quarter. J. Stern & Co. LLP now owns 45,448,168 shares of the industrial products company’s stock valued at $6,189,132,000 after acquiring an additional 45,082,435 shares during the last quarter. Norges Bank bought a new position in shares of Xylem in the fourth quarter worth about $361,012,000. Balyasny Asset Management L.P. boosted its stake in shares of Xylem by 346.2% in the 3rd quarter. Balyasny Asset Management L.P. now owns 712,950 shares of the industrial products company’s stock valued at $105,160,000 after purchasing an additional 553,152 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Xylem in the 2nd quarter valued at approximately $64,407,000. Finally, SG Americas Securities LLC grew its holdings in shares of Xylem by 255.4% during the 1st quarter. SG Americas Securities LLC now owns 681,904 shares of the industrial products company’s stock valued at $81,488,000 after purchasing an additional 490,040 shares during the last quarter. 87.96% of the stock is owned by institutional investors and hedge funds.

Xylem Stock Performance

Shares of Xylem stock opened at $120.82 on Tuesday. The stock has a market cap of $28.72 billion, a price-to-earnings ratio of 30.05, a P/E/G ratio of 1.75 and a beta of 1.03. Xylem Inc. has a twelve month low of $105.29 and a twelve month high of $154.27. The company’s fifty day moving average is $113.40 and its 200 day moving average is $123.26. The company has a quick ratio of 1.10, a current ratio of 1.46 and a debt-to-equity ratio of 0.13.

Xylem (NYSE:XYL) last announced its earnings results on Tuesday, April 28th. The industrial products company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.03. The business had revenue of $2.12 billion during the quarter, compared to analyst estimates of $2.11 billion. Xylem had a return on equity of 11.26% and a net margin of 10.79%.Xylem’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the company earned $1.03 EPS. Xylem has set its FY 2026 guidance at 5.350-5.600 EPS. Sell-side analysts forecast that Xylem Inc. will post 5.51 EPS for the current year.

Xylem Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Thursday, May 28th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend was Thursday, May 28th. Xylem’s payout ratio is currently 42.79%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. CLSA upgraded shares of Xylem to a “hold” rating in a research report on Thursday, June 25th. Barclays decreased their target price on shares of Xylem from $156.00 to $154.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. Jefferies Financial Group upgraded Xylem from a “hold” rating to a “buy” rating and increased their price target for the company from $130.00 to $140.00 in a research note on Thursday, June 25th. Weiss Ratings downgraded Xylem from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 8th. Finally, JPMorgan Chase & Co. reduced their price objective on Xylem from $170.00 to $160.00 and set an “overweight” rating on the stock in a research report on Thursday, April 16th. Eight equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $153.15.

Insider Activity at Xylem

In related news, CAO Geri-Michelle Mcshane sold 4,269 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $117.46, for a total value of $501,436.74. Following the sale, the chief accounting officer directly owned 3,605 shares in the company, valued at $423,443.30. This represents a 54.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jerome A. Peribere bought 1,210 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were purchased at an average cost of $116.61 per share, with a total value of $141,098.10. Following the transaction, the director directly owned 27,209 shares in the company, valued at approximately $3,172,841.49. This trade represents a 4.65% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.32% of the company’s stock.

About Xylem

Xylem Inc (NYSE: XYL) is a global water technology company that designs, manufactures and services engineered systems and equipment for the transport, treatment, testing and efficient use of water. Its product portfolio spans pumps and pumping systems, valves, filtration and disinfection equipment, sensors and analytical instruments, and digital solutions for monitoring and control of water infrastructure. Xylem serves the full water cycle with offerings for water and wastewater utilities, industrial customers, commercial and residential buildings, and agricultural applications.

The company was established as an independent publicly traded company in 2011 following a corporate spin-off from ITT Corporation and is headquartered in Rye Brook, New York.